Literature DB >> 30698829

The contribution of active and passive mechanisms of 5mC and 5hmC removal in human T lymphocytes is differentiation- and activation-dependent.

Lucia Vincenzetti1, Cristina Leoni1, Michele Chirichella1, Ivo Kwee1, Silvia Monticelli1.   

Abstract

In mammals, the 5'-methylcytosine (5mC) modification in the genomic DNA contributes to the dynamic control of gene expression. 5mC erasure is required for the activation of developmental programs and occurs either by passive dilution through DNA replication, or by enzymatic oxidation of the methyl mark to 5-hydroxymethylcytosine (5hmC), which can persist as such or undergo further oxidation and enzymatic removal. The relative contribution of each mechanism to epigenetic control in dynamic biological systems still remains a compelling question. To explore this critical issue, we used primary human T lymphocytes, in which two cellular states can be clearly identified, namely quiescent naïve T cells, which are slowly or rarely proliferating, and rapidly proliferating activated T cells. We found that active mechanisms of methylation removal were selectively at work in naïve T cells, while memory T lymphocytes entirely relied on passive, replication-dependent dilution, suggesting that proliferative capacity influences the choice of the preferential demethylation mechanism. Active processes of demethylation appear to be critical in quiescent naïve T lymphocytes for the maintenance of regulatory regions poised for rapid responses to physiological stimuli.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Activation; DNA methylation; Differentiation; Epigenetics; T lymphocytes

Mesh:

Substances:

Year:  2019        PMID: 30698829     DOI: 10.1002/eji.201847967

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  The Methylation Game: Epigenetic and Epitranscriptomic Dynamics of 5-Methylcytosine.

Authors:  Adele Alagia; Monika Gullerova
Journal:  Front Cell Dev Biol       Date:  2022-06-03

Review 2.  Deciphering the multifaceted roles of TET proteins in T-cell lineage specification and malignant transformation.

Authors:  Ageliki Tsagaratou
Journal:  Immunol Rev       Date:  2021-01-07       Impact factor: 12.988

3.  Epigenomics and gene regulation in mammalian social systems.

Authors:  Tania P Guerrero; Jörns Fickel; Sarah Benhaiem; Alexandra Weyrich
Journal:  Curr Zool       Date:  2020-02-25       Impact factor: 2.624

Review 4.  TET-Mediated Epigenetic Regulation in Immune Cell Development and Disease.

Authors:  Nikolas James Tsiouplis; David Wesley Bailey; Lilly Felicia Chiou; Fiona Jane Wissink; Ageliki Tsagaratou
Journal:  Front Cell Dev Biol       Date:  2021-01-15

5.  Antigenic Challenge Influences Epigenetic Changes in Antigen-Specific T Regulatory Cells.

Authors:  Dorota Iwaszkiewicz-Grzes; Magdalena Piotrowska; Mateusz Gliwinski; Zuzanna Urban-Wójciuk; Piotr Trzonkowski
Journal:  Front Immunol       Date:  2021-03-23       Impact factor: 7.561

Review 6.  Logic and lineage impacts on functional transcription factor deployment for T-cell fate commitment.

Authors:  Ellen V Rothenberg
Journal:  Biophys J       Date:  2021-04-08       Impact factor: 3.699

7.  RFX transcription factors control a miR-150/PDAP1 axis that restrains the proliferation of human T cells.

Authors:  Michele Chirichella; Niccolò Bianchi; Emina Džafo; Elena Foli; Francesco Gualdrini; Amy Kenyon; Gioacchino Natoli; Silvia Monticelli
Journal:  PLoS Biol       Date:  2022-02-10       Impact factor: 8.029

Review 8.  Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.

Authors:  Qingyang Xiao; André Nobre; Pilar Piñeiro; Miguel-Ángel Berciano-Guerrero; Emilio Alba; Manuel Cobo; Volker M Lauschke; Isabel Barragán
Journal:  J Clin Med       Date:  2020-01-20       Impact factor: 4.241

9.  Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade.

Authors:  Isabel Barragan
Journal:  EBioMedicine       Date:  2020-09-26       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.